Faron Historical Balance Sheet

FARN Stock

170.00 2.50 1.49%

Trend analysis of Faron Pharmaceuticals Oy balance sheet accounts such as Other Current Liabilities of 2.7 M or Total Current Liabilities of 15.8 M provides information on Faron Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Faron Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Faron Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Faron Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Faron Pharmaceuticals is a good buy for the upcoming year.

Faron Pharmaceuticals Inventory

0.0

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Faron Pharmaceuticals Oy. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Faron Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Faron Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Faron Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Faron Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Faron currently owns. An asset can also be divided into two categories, current and non-current.

Faron Pharmaceuticals Balance Sheet Chart

At this time, Faron Pharmaceuticals' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 10.9 M in 2024, despite the fact that Retained Earnings are likely to grow to (163.6 M).

Total Assets Short Long Term Debt Total Total Current Liabilities Retained Earnings Accounts Payable Long Term Debt

Add Fundamental

Total Assets

Total assets refers to the total amount of Faron Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Faron Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Faron Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Faron Pharmaceuticals Oy are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Accounts Payable

An accounting item on the balance sheet that represents Faron Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Faron Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Long Term Debt

Long-term debt is a debt that Faron Pharmaceuticals has held for over one year. Long-term debt appears on Faron Pharmaceuticals Oy balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Faron Pharmaceuticals Oy balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most accounts from Faron Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Faron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Faron Pharmaceuticals Oy. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	3.5M	13.3M	13.1M	13.8M
Total Assets	13.2M	11.3M	10.2M	10.5M

Short Long Term Debt Total Total Assets

Faron Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Non Current Assets Total	Long Term Debt	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Net Tangible Assets	Short Long Term Debt	Cash	Cash And Short Term Investments
Total Assets		0.21	0.7	0.49	0.27	0.38	-0.59	-0.42	0.42	0.25	0.24	0.67	0.68	0.4	0.24	0.79	0.36	0.4	1.0	-0.04	-0.43	0.75	0.34	-0.44	0.98	0.98
Short Long Term Debt Total	0.21		0.26	0.86	-0.85	0.68	0.65	-0.85	0.88	0.55	0.99	0.16	0.24	0.74	0.99	0.19	0.86	0.95	0.19	0.88	0.14	0.38	-0.81	0.67	0.19	0.19
Other Current Liab	0.7	0.26		0.61	-0.06	0.7	-0.26	-0.62	0.46	0.46	0.31	0.82	0.55	0.6	0.33	0.89	0.45	0.51	0.69	0.05	-0.59	0.77	-0.01	-0.37	0.61	0.61
Total Current Liabilities	0.49	0.86	0.61		-0.68	0.86	0.34	-0.95	0.98	0.58	0.85	0.56	0.45	0.8	0.86	0.55	0.91	0.97	0.48	0.74	-0.3	0.67	-0.58	0.38	0.44	0.44
Total Stockholder Equity	0.27	-0.85	-0.06	-0.68		-0.6	-0.92	0.71	-0.71	-0.46	-0.83	0.02	0.07	-0.6	-0.84	0.09	-0.72	-0.77	0.29	-0.87	-0.18	-0.1	0.98	-0.81	0.3	0.3
Current Deferred Revenue	0.38	0.68	0.7	0.86	-0.6		0.3	-0.92	0.79	0.35	0.68	0.6	0.32	0.87	0.71	0.62	0.78	0.82	0.37	0.47	-0.4	0.54	-0.54	0.16	0.3	0.3
Net Debt	-0.59	0.65	-0.26	0.34	-0.92	0.3		-0.41	0.4	0.29	0.63	-0.32	-0.35	0.34	0.63	-0.38	0.42	0.49	-0.61	0.74	0.43	-0.26	-0.95	0.87	-0.61	-0.61
Retained Earnings	-0.42	-0.85	-0.62	-0.95	0.71	-0.92	-0.41		-0.9	-0.46	-0.85	-0.48	-0.4	-0.92	-0.87	-0.58	-0.87	-0.94	-0.41	-0.68	0.21	-0.64	0.64	-0.32	-0.35	-0.35
Accounts Payable	0.42	0.88	0.46	0.98	-0.71	0.79	0.4	-0.9		0.53	0.86	0.45	0.39	0.74	0.86	0.42	0.93	0.96	0.4	0.79	-0.25	0.6	-0.62	0.47	0.38	0.38
Non Current Assets Total	0.25	0.55	0.46	0.58	-0.46	0.35	0.29	-0.46	0.53		0.57	0.47	0.16	0.4	0.56	0.34	0.45	0.59	0.21	0.45	-0.18	0.33	-0.44	0.28	0.21	0.21
Long Term Debt	0.24	0.99	0.31	0.85	-0.83	0.68	0.63	-0.85	0.86	0.57		0.19	0.25	0.76	1.0	0.23	0.86	0.95	0.22	0.85	0.14	0.41	-0.8	0.62	0.22	0.22
Net Receivables	0.67	0.16	0.82	0.56	0.02	0.6	-0.32	-0.48	0.45	0.47	0.19		0.19	0.47	0.2	0.82	0.38	0.41	0.66	-0.05	-0.75	0.55	0.07	-0.35	0.58	0.58
Common Stock Total Equity	0.68	0.24	0.55	0.45	0.07	0.32	-0.35	-0.4	0.39	0.16	0.25	0.19		0.32	0.26	0.46	0.41	0.38	0.68	0.16	-0.22	0.79	0.16	-0.23	0.7	0.7
Common Stock Shares Outstanding	0.4	0.74	0.6	0.8	-0.6	0.87	0.34	-0.92	0.74	0.4	0.76	0.47	0.32		0.78	0.58	0.74	0.82	0.39	0.51	-0.09	0.56	-0.57	0.2	0.36	0.36
Non Current Liabilities Total	0.24	0.99	0.33	0.86	-0.84	0.71	0.63	-0.87	0.86	0.56	1.0	0.2	0.26	0.78		0.24	0.87	0.95	0.22	0.84	0.12	0.42	-0.81	0.6	0.22	0.22
Other Current Assets	0.79	0.19	0.89	0.55	0.09	0.62	-0.38	-0.58	0.42	0.34	0.23	0.82	0.46	0.58	0.24		0.33	0.43	0.79	-0.07	-0.6	0.68	0.15	-0.46	0.69	0.69
Other Stockholder Equity	0.36	0.86	0.45	0.91	-0.72	0.78	0.42	-0.87	0.93	0.45	0.86	0.38	0.41	0.74	0.87	0.33		0.93	0.34	0.71	-0.27	0.6	-0.65	0.39	0.35	0.35
Total Liab	0.4	0.95	0.51	0.97	-0.77	0.82	0.49	-0.94	0.96	0.59	0.95	0.41	0.38	0.82	0.95	0.43	0.93		0.38	0.81	-0.12	0.58	-0.71	0.49	0.35	0.35
Total Current Assets	1.0	0.19	0.69	0.48	0.29	0.37	-0.61	-0.41	0.4	0.21	0.22	0.66	0.68	0.39	0.22	0.79	0.34	0.38		-0.06	-0.43	0.74	0.36	-0.45	0.98	0.98
Short Term Debt	-0.04	0.88	0.05	0.74	-0.87	0.47	0.74	-0.68	0.79	0.45	0.85	-0.05	0.16	0.51	0.84	-0.07	0.71	0.81	-0.06		0.27	0.27	-0.81	0.86	-0.06	-0.06
Intangible Assets	-0.43	0.14	-0.59	-0.3	-0.18	-0.4	0.43	0.21	-0.25	-0.18	0.14	-0.75	-0.22	-0.09	0.12	-0.6	-0.27	-0.12	-0.43	0.27		-0.4	-0.25	0.49	-0.37	-0.37
Common Stock	0.75	0.38	0.77	0.67	-0.1	0.54	-0.26	-0.64	0.6	0.33	0.41	0.55	0.79	0.56	0.42	0.68	0.6	0.58	0.74	0.27	-0.4		-0.02	-0.25	0.72	0.72
Net Tangible Assets	0.34	-0.81	-0.01	-0.58	0.98	-0.54	-0.95	0.64	-0.62	-0.44	-0.8	0.07	0.16	-0.57	-0.81	0.15	-0.65	-0.71	0.36	-0.81	-0.25	-0.02		-0.78	0.38	0.38
Short Long Term Debt	-0.44	0.67	-0.37	0.38	-0.81	0.16	0.87	-0.32	0.47	0.28	0.62	-0.35	-0.23	0.2	0.6	-0.46	0.39	0.49	-0.45	0.86	0.49	-0.25	-0.78		-0.43	-0.43
Cash	0.98	0.19	0.61	0.44	0.3	0.3	-0.61	-0.35	0.38	0.21	0.22	0.58	0.7	0.36	0.22	0.69	0.35	0.35	0.98	-0.06	-0.37	0.72	0.38	-0.43		1.0
Cash And Short Term Investments	0.98	0.19	0.61	0.44	0.3	0.3	-0.61	-0.35	0.38	0.21	0.22	0.58	0.7	0.36	0.22	0.69	0.35	0.35	0.98	-0.06	-0.37	0.72	0.38	-0.43	1.0

Click cells to compare fundamentals

Faron Pharmaceuticals Account Relationship Matchups

Faron Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	10.2M	8.4M	13.2M	11.3M	10.2M	10.5M
Short Long Term Debt Total	2.8M	3.2M	3.5M	13.3M	13.1M	13.8M
Other Current Liab	2.8M	4.1M	4.3M	3.3M	2.4M	2.7M
Total Current Liabilities	6.1M	6.5M	7.2M	10.5M	15.0M	15.8M
Total Stockholder Equity	1.6M	(1.8M)	2.9M	(11.5M)	(15.2M)	(14.4M)
Net Debt	(4.2M)	(883K)	(3.3M)	6.3M	6.2M	6.5M
Retained Earnings	(80.0M)	(96.6M)	(116.3M)	(143.7M)	(172.2M)	(163.6M)
Accounts Payable	3.0M	2.1M	2.2M	5.1M	9.0M	9.4M
Non Current Assets Total	1.0M	996K	1.2M	1.5M	1.4M	1.3M
Long Term Debt	2.3M	2.7M	2.9M	11.1M	9.4M	9.9M
Net Receivables	1.3M	1.3M	1.4M	905K	1.0M	981.9K
Common Stock Shares Outstanding	39.9K	46.8K	51.8K	60.1K	68.8K	40.5K
Liabilities And Stockholders Equity	10.2M	8.4M	13.2M	11.3M	10.2M	10.5M
Non Current Liabilities Total	2.5M	3.7M	3.1M	12.3M	10.4M	10.9M
Other Current Assets	2.1M	3.3M	5.2M	2.7M	2.0M	2.5M
Other Stockholder Equity	78.8M	91.9M	(1K)	129.4M	154.2M	161.9M
Total Liab	8.6M	10.2M	10.3M	22.7M	25.4M	26.7M
Total Current Assets	9.2M	7.4M	12.0M	9.7M	8.9M	9.2M
Accumulated Other Comprehensive Income	78.9K	92.0K	116.5K	129.5K	154.4K	162.1K
Intangible Assets	529K	565K	899K	1.2M	1.1M	691.5K
Net Tangible Assets	1.1M	(2.4M)	2.0M	(12.6M)	(11.4M)	(10.8M)
Short Long Term Debt	163K	122K	429K	1.9M	3.5M	3.6M
Cash	7.1M	4.1M	6.9M	7.0M	6.9M	5.4M
Cash And Short Term Investments	7.1M	4.1M	6.9M	7.0M	6.9M	5.4M
Property Plant And Equipment Net	399K	375K	207K	327K	204K	195.6K
Property Plant And Equipment Gross	399K	375K	207K	327K	225K	198.1K
Property Plant Equipment	399K	375K	207K	327K	376.1K	192.0K
Non Currrent Assets Other	77K	56K	53K	60K	54K	51.3K
Net Invested Capital	4.0M	1.0M	6.3M	1.5M	(2.3M)	(2.1M)
Net Working Capital	3.1M	868K	4.8M	(741K)	(6.1M)	(5.8M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Faron Stock Analysis

When running Faron Pharmaceuticals' price analysis, check to measure Faron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Faron Pharmaceuticals is operating at the current time. Most of Faron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Faron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Faron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Faron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC